In defense. Well, I didn't here that from IR so would need to sort through the truth there. They haven't missed any deadlines literally....just missed on their expectation of filing early. Extensions are common in OTC. And the delay is due to acquisitions and LOI. So at least we are moving forward on the actual business of revenue and mass distribution. As they stated in the q3 pr they were hoping to file early if all parties got there paperwork in. And there is the issue of a new auditor.
Main issue here is over-promising on early filings....and even in this case they did get some info on Q3 out early. Tighten up ur game management. Follow BBio lead.